TScan Therapeutics announces ~$30M direct offering (NASDAQ:TCRX)

[ad_1]

  • Biotechnology company TScan Therapeutics (NASDAQ:TCRX) announced on Thursday the sale of ~$30M of pre-funded warrants to purchase up to an aggregate of 7.5M voting shares at $4.00 per pre-funded warrant.
  • TCRX has entered into a securities purchase agreement with Lynx1

[ad_2]

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *